News
Public · Published
Cantor Fitzgerald maintains Eli Lilly at Overweight, raises price target to $1600 from $1440
Cantor Fitzgerald kept its Overweight rating on Eli Lilly and raised its price target to $1600 from $1440, an 11.1% increase. The new target was 12.9% above the stock's October 30 closing price of $1417.54.
Published:
Updated:
What happened
Cantor Fitzgerald kept its Overweight rating on Eli Lilly and raised its price target to $1600 from $1440, an 11.1% increase. The new target was 12.9% above the stock’s October 30 closing price of $1417.54.
Confirmed
Global impact / market context
A higher price target signals that Cantor Fitzgerald sees more potential value in Eli Lilly shares, but it is an analyst estimate rather than a company result or guarantee. If investors act on it, buying could support the share price; the article reports no market reaction.
Analyst inference
The five most recent analyst notes in the article set targets between $1596 and $1650, placing Cantor Fitzgerald’s $1600 target near the low end of that range. This shows its revised estimate is broadly within the reported analyst range, not an outlier.
Confirmed
What to watch
- Compare future analyst targets with company results and guidance; those measures can show whether expectations for Eli Lilly’s sales and earnings are being met. Analyst inference
- Watch for additional rating or target changes in the article’s stated analyst group; further revisions could shift investor expectations for the shares. Analyst inference
- The reported $1600 target is an analyst estimate, not a promised share price; the article gives no company forecast or explanation for the revision. Confirmed
Evidence
- Original source link unavailable